Actively Recruiting
The Efficacy of Lymph Node Dissection for Stage IIICr of Cervical Cancer(CQGOG0103)
Led by Chongqing University Cancer Hospital · Updated on 2025-09-02
452
Participants Needed
1
Research Sites
602 weeks
Total Duration
On this page
Sponsors
C
Chongqing University Cancer Hospital
Lead Sponsor
S
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Collaborating Sponsor
AI-Summary
What this Trial Is About
This is an national, prospective, multicenter and randomized clinical study designed to determine if patients with stage IIICr of cervical cancer have longer PFS and/or OS with lymph node dissection before CCRT when compared to CCRT.
CONDITIONS
Official Title
The Efficacy of Lymph Node Dissection for Stage IIICr of Cervical Cancer(CQGOG0103)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with squamous cell carcinoma, adenocarcinoma, or adeno-squamous cell carcinoma of the cervix
- Stage IIICr cervical cancer confirmed by CT, MRI, or PET/CT with image-positive lymph nodes at least 15 mm in short diameter
- ECOG performance status of 0 or 1
- Expected survival longer than 6 months
- Negative serum or urine pregnancy test within 7 days before enrollment for women of childbearing age who agree to use contraception during the trial
- No contraindications to surgery
You will not qualify if you...
- Active or uncontrolled severe infection
- Active hepatitis B, liver cirrhosis, or decompensated liver disease
- History of immune deficiency including HIV or other immunodeficiency diseases
- Active autoimmune disease requiring systemic treatment such as corticosteroids or immunosuppressants
- History of pneumonitis requiring steroids or current pneumonitis
- Chronic kidney failure or insufficiency
- Other malignant tumors diagnosed within the past 5 years or requiring treatment
- History of myocardial infarction, severe arrhythmia, or congestive heart failure NYHA class 2 or higher
- Previous allogenic tissue or solid organ transplant
- History of pelvic artery embolization
- History of pelvic radiotherapy
- History of partial or radical hysterectomy
- Previous or current immunotherapy
- History of severe allergic reactions to platinum chemotherapy, pembrolizumab, or related substances
- Use of medications causing serious liver or kidney impairment during treatment, such as tuberculosis drugs
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Chongqing Cancer Hospital
Chongqing, Chongqing Municipality, China, 400030
Actively Recruiting
Research Team
D
Dongling Zou, M.D.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here